OPT lists on Euronext Growth Milan after 2 million euro IPO raise

Traders Union
All News
Financial Institutions
OPT lists on Euronext Growth

Highlights

OPT raised 2 million euros in its IPO, with 1.8 million euros excluding the over-allotment option, and listed on Euronext Growth Milan on 26 June.
At admission, OPT's free float stands at 33.68% and market capitalisation at IPO totals 5.3 million euros, rising to 5.5 million euros if the over-allotment option is fully exercised.
OPT specializes in Healthcare High Value-Added Services, targeting efficiency improvements for public and private healthcare and pharmaceutical-sponsored programs.

IPO terms and listing details

Euronext said on 26 June that OPT has joined Euronext Growth Milan, giving the company a public market platform to support its operations in healthcare high value-added services.

During the placement phase, OPT raises 2 million euros including the potential exercise of the over-allotment option. Excluding that option, the total amount raised is 1.8 million euros. The free float at admission stands at 33.68%, while market capitalisation at the IPO amounts to 5.3 million euros, or 5.5 million euros assuming full exercise of the over-allotment option.

Healthcare services focus and market context

OPT designs and delivers services for healthcare in clinical and organisational areas, serving both public and private healthcare systems as well as pharmaceutical-sponsored programmes. Its business is positioned around what it calls Healthcare High Value-Added Services, aimed at supporting care delivery and system efficiency.

Chief Executive Officer Davide Lucano says these services are becoming more important in the evolution of modern healthcare systems because they help integrate the needs of hospitals, pharmaceutical and medtech companies, patients and institutions across the care pathway. He says OPT’s role is to support more efficient clinical and organisational models, encourage appropriate therapy adoption, strengthen pathway monitoring and generate evidence that improves coordination, sustainability and patient experience.

Our earlier coverage of SpaceX’s post-IPO volatility looked at the sharp price swings that followed an initial surge above its IPO price, driven largely by retail momentum and sentiment rather than near-term earnings. We also noted investor concerns about valuation, heavy losses and cash burn, and the impact of limited free float and potential additional share supply on trading after the listing.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

OPT lists on Euronext Growth Milan after 2 million euro IPO raise

Highlights

IPO terms and listing details

Healthcare services focus and market context

Editor's Picks for You